Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cytokinetics
(NQ:
CYTK
)
59.53
-0.39 (-0.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cytokinetics
< Previous
1
2
3
4
5
6
Next >
Analyst Ratings for Cytokinetics
December 20, 2022
Via
Benzinga
Expert Ratings for Cytokinetics
December 20, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
December 20, 2022
Via
Benzinga
What 7 Analyst Ratings Have To Say About Cytokinetics
December 20, 2022
Via
Benzinga
FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate
December 14, 2022
Via
Benzinga
Where Cytokinetics Stands With Analysts
October 11, 2022
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Analyst Ratings for Cytokinetics
July 15, 2022
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
December 14, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Via
Benzinga
Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said
December 14, 2022
Via
Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
December 14, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Where Cytokinetics Stands With Analysts
May 24, 2022
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:
Via
Benzinga
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug
December 14, 2022
The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug.
Via
Investor's Business Daily
Top Stories Today: Jack Dorsey Not Exactly Impressed With Elon Musk's Twitter; Binance Sees $3B Outflow In 7 Days..
December 14, 2022
Benzinga
Via
Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Via
Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
October 25, 2022
The company hopes to come out next year with at least one heart-failure drug.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306%
October 03, 2022
Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20...
Via
Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
September 07, 2022
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
Via
Benzinga
Swing Trading Stock Watchlist For The Week Of Sept. 6
September 04, 2022
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look.
Via
Talk Markets
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
August 08, 2022
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
What 5 Analyst Ratings Have To Say About Cytokinetics
August 05, 2022
Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter:
Via
Benzinga
Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M
August 05, 2022
Via
Benzinga
Recap: Cytokinetics Q2 Earnings
August 04, 2022
Cytokinetics (NASDAQ:CYTK) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics beat estimated...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 30, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 29, 2022
Gainers
Via
Benzinga
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
June 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
What 5 Analyst Ratings Have To Say About Cytokinetics
June 10, 2022
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:
Via
Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
May 22, 2022
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.
Via
Benzinga
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
May 22, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing...
Via
Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
May 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.